Decision-Making Analysis for Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer: A Survey by the Executive Committee of the Peritoneal Surface Oncology Group International (PSOGI).

Steffen, Thomas; Häller, Lukas; Bijelic, Lana; Glatzer, Markus; Glehen, Olivier; Goéré, Diane; de Hingh, Ignace; Li, Yan; Moran, Brendan J; Morris, David L; Piso, Pompiliu; Quadros, Claudio A; Rau, Beate; Sugarbaker, Paul; Yonemura, Yutaka; Putora, Paul M (2021). Decision-Making Analysis for Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer: A Survey by the Executive Committee of the Peritoneal Surface Oncology Group International (PSOGI). Oncology - international journal of cancer research and treatment, 99(1), pp. 41-48. Karger 10.1159/000510098

Full text not available from this repository. (Request a copy)

OBJECTIVES

To assess the individual treatment strategies among international experts in peritoneal carcinosis, specifically their decision-making in the process of patient selection for hyperthermic intraperitoneal chemotherapy (HIPEC) in women suffering from ovarian cancer, to identify relevant decision-making criteria, and to quantify the level of consensus for or against HIPEC.

METHODS

The members of the executive committee of the Peritoneal Surface Oncology Group International (PSOGI) were asked to describe the clinical conditions under which they would recommend HIPEC in patients with ovarian cancer and to describe any disease or patient characteristics relevant to their decision. All answers were then merged and converted into decision trees. The decision trees were then analyzed by applying the objective consensus methodology.

RESULTS

Nine experts in surgical oncology provided information on their multidisciplinary treatment strategy including HIPEC for patients with advanced ovarian cancer. Three of the total of 12 experts did not perform HIPEC. Five criteria relevant to the decision on whether HIPEC is performed were applied. In patients with resectable disease, a peritoneal cancer index (PCI) <21, and epithelial ovarian cancer without distant metastasis, consent was received by 75% to perform HIPEC for women suffering from recurrent disease. Furthermore, in the primary disease setting, consent was received by 67% to perform HIPEC according to the same criteria.

DISCUSSION AND CONCLUSION

Among surgical oncology experts in peritoneal surface malignancy and HIPEC, HIPEC plays an important role in primary and recurrent ovarian cancer, and the PCI is the most important criterion in this decision.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Radiation Oncology

UniBE Contributor:

Putora, Paul Martin

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0030-2414

Publisher:

Karger

Language:

English

Submitter:

Ramona Wenholt

Date Deposited:

05 Nov 2020 17:13

Last Modified:

06 Jan 2021 01:32

Publisher DOI:

10.1159/000510098

PubMed ID:

32920557

Uncontrolled Keywords:

Chemotherapy Hyperthermic intraperitoneal chemotherapy Metastasis Ovarian cancer Peritoneal carcinomatosis Peritoneal malignancy

URI:

https://boris.unibe.ch/id/eprint/147329

Actions (login required)

Edit item Edit item
Provide Feedback